Monthly Archives: March 2017

Caveat Subscriptor When Academia Touts A Breakthrough
March 31, 2017

This blog was written by Nessan Bermingham, CEO of Intellia Therapeutics, as part of the From The Trenches feature of LifeSciVC   Academic discoveries are oxygen for entrepreneurs. But, caveat subscriptor – be careful what you sign. Even high profile

1 Comment

The Inescapable Gravity Of Biotech’s Key Clusters: The Great Consolidation Of Talent, Capital, & Returns
March 21, 2017

Two key geographic clusters dominate the biotech landscape today. These two areas, Boston and San Francisco, combine a unique blend of biomedical science, venture capital, entrepreneurial talent, risk-taking culture, and geographic density. Other regions have some or all of these


The Hunt For Novel Treatments Against Deadly Bacteria:  Spero Therapeutics And Its Potentiators
March 16, 2017

This guest blog was written by Troy Lister, Head of Chemistry, and Cristina Larkin, Chief Commercial Officer, of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. A national security threat equivalent to terrorism?  This is how

1 Comment

Of Abundance And Scarcity In Venture Capital
March 13, 2017

As a biotech investor, it’s been fascinating to watch the Snapchat IPO and the fanfare around this $25B sensation following its offering as a “camera” company. As one of the big tech unicorns, it’s justifiably gotten considerable attention in the

1 Comment

VC-Backed Biotech Ecosystem: A Market In Healthy Equilibrium
March 10, 2017

Despite the volatility of biotech stocks in the public markets, the VC-backed private biotech ecosystem has been in remarkable equilibrium for much of the last decade. e·qui·lib·ri·um. noun.  a state in which opposing forces or influences are balanced. As I’ve noted